Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
δ-Aminolevulinic acid synthetase (ALAS)
- Target
- ALAS
- Molecular classification
- Enzyme, Transferase, Acyltransferase
01
Overview
δ-Aminolevulinic acid synthetase (ALAS) is a mitochondrial enzyme that catalyzes the first and rate-limiting step in the heme biosynthetic pathway. It condenses glycine and succinyl-CoA to form δ-aminolevulinic acid (ALA). There are two main isoforms: ALAS1 (housekeeping) and ALAS2 (erythroid-specific). Mutations or dysregulation can lead to disorders such as sideroblastic anemia or porphyrias due to impaired heme synthesis pathways.
02
Mechanism of action
Inhibition of δ-aminolevulinic acid synthesis
03
Biological functions
Heme synthesisPorphyrin biosynthesis
04
Disease associations
Sideroblastic anemiaPorphyria
05
Safety considerations
Accumulation of porphyrin precursorsDrug-induced porphyria
06
Biomarkers
ALA levelsPorphyrin levels
Beyond the preview
Go deeper on δ-Aminolevulinic acid synthetase (ALAS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on δ-Aminolevulinic acid synthetase (ALAS).